Not Signed In - Ranbaxy Is Granted Final Approval To Manufacture And Market Cefprozil Anti- Infective Tablets
Fri, 15 Dec 2006 08:00 AM EST
... Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Cefprozil Tablets USP, 250 mg and 500 mg. The Office of Generic Drugs, U.S. [click link for full article] ...
Related Topics
- Cefprozil
- Research
- Wrinkles
- Carbinoxamine and Pseudoephedrine Tablets
- Virus
- Drug and Medical Device Safety
- Cerivastatin - Withdrawn From The Market
- Aging Skin
- Vaccine Testing & Approval
- Carbinoxamine and Pseudoephedrine Extended-Release Tablets
- Aging
- Cyanocobalamin Tablets
- Tragacanth
- Chlorpheniramine, Pseudoephedrine and Hydrocodone Tablets
- Guaifenesin and Dextromethorphan
- Neostigmine Tablets
- Haloperidol Tablets
- Thiabendazole Tablets
- Rofecoxib Oral Suspension
- Carbetapentane, Phenylephrine, and Pyrilamine
email this page
print this page
bookmark this page
feedback on this page
